Crossref
Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients
Clinical Oncology · 2026-06 · 54 · 104109
DOI: 10.1016/j.clon.2026.104109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oncology, 2026-06. Verfasst von Nity Singh und 2 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Singh, N., Hairudin, T., & Singh, G. (2026). Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients. Clinical Oncology, 54, 104109. https://doi.org/10.1016/j.clon.2026.104109
Vancouver
Singh N, Hairudin T, Singh G. Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients. Clinical Oncology. 2026;54:104109. doi:10.1016/j.clon.2026.104109
BibTeX
@article{Singh2026,
author = {Singh, Nity and Hairudin, Taufik and Singh, Govind},
title = {Real world experience of using oral Systemic Anti Cancer Therapy (Abiraterone, Apalutamide and Enzalutamide) in advanced hormone-sensitive prostate cancer patients},
journal = {Clinical Oncology},
year = {2026},
volume = {54},
pages = {104109},
doi = {10.1016/j.clon.2026.104109}
}
EUVIMED